应对恶性血液肿瘤在新型冠状病毒肺炎疫情中的挑战（英文）

发布时间：2022-08-23 22:35

　　新型冠状病毒肺炎（COVID-19）是一种由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的新型传染病。SARS-CoV-2具有极强的传染性,因此在引发流行病后又使其迅速升级为全球大流行,至今仍在部分国家迅速传播。在COVID-19的感染者中,存在肿瘤等慢性病或伴有相关合并症的患者预后往往较差。同时,由于恶性血液肿瘤患者长期处于免疫抑制状态,往往感染风险更高且预后更差,所以十分值得我们关注。这篇综述归纳并分析了恶性血液肿瘤患者合并COVID-19后的临床表现。此外,归纳了疫情期间恶性肿瘤的管理策略和感染后的综合干预措施,旨在为临床提供指导。 

【文章页数】：19 页

【文章目录】：
1 Introduction
2 Regional reports of SARS-Co V-2 infections in patients with HMs
3 Specific clinical manifestations,radiologic patterns,and laboratory findings in patients with COVID-19 and HMs
    3.1 Clinical manifestations
    3.2 Radiologic findings
    3.3 Laboratory tests
4 Clinical diagnostic criteria and differential diagnoses of patients with COVID-19 and HMs
5 General management strategies for patients with HMs during the COVID-19 pandemic
    5.1 Considerations for hospital admission procedures
    5.2 Considerations for hematological therapeutic regimens
        5.2.1 Chemotherapy
        5.2.2 Immunotherapy
        5.2.3 Hematopoietic stem cell transplantation
        5.2.4 Recommendations for regimen adjustments
            5.2.4. 1 Acute leukemia
            5.2.4. 2 Chronic leukemia
            5.2.4. 3 Lymphoma
            5.2.4. 4 Multiple myeloma
    5.3 Considerations for follow-up plans
6 Comprehensive intervention strategies for patients with COVID-19 and preexisting HMs
7 Conclusions
Contributors
Compliance with ethics guidelines


【参考文献】：
期刊论文
[1]2019冠状病毒病流行期间儿童血液肿瘤病房规范化管理建议[J]. 邱奕宁,李力,吴小艳,金润铭.  中国当代儿科杂志. 2020(03)



本文编号：3678608